Department of Neonatology, Huaibei Maternal and Child Health Hospital, Huaibei, Anhui Province, China.
Medicine (Baltimore). 2023 Mar 3;102(9):e33142. doi: 10.1097/MD.0000000000033142.
To compare the safety and effectiveness of nasal noninvasive high- frequency oscillatory ventilation (NHFOV) and duo positive airway pressure (DuoPAP) applications in preterm babies with respiratory distress syndrome (RDS).
This was a randomized controlled trial. Forty-three premature infants with RDS treated in the neonatal intensive care unit of Huaibei Maternal and Child Health Hospital from January 2020 to November 2021 were selected as the research participants. They were randomly divided into the NHFOV group (n = 22) and DuoPAP group (n = 21). General conditions, including the arterial oxygen partial pressure (PaO2), carbon dioxide partial pressure (PaCO2), oxygenation index (OI), the incidence of apnea at 72 hours, duration of noninvasive respiratory support, maternal high-risk factors, total oxygen consumption time, total gastrointestinal feeding time, and the frequency of intraventricular hemorrhage (IVH), neonatal necrotizing enterocolitis (NEC), and bronchopulmonary dysplasia (BPD) and apnea were compared between the NHFOV group and DuoPAP group at 12 and 24 hours after noninvasive respiratory support.
There was no noteworthy difference between the 2 groups with respect to PaO2, PaCO2, OI, IVH, and NEC and BPD at different nodes (all P > .05).
The endpoints of PaO2, PaCO2 and OI and complications of IVH, NEC, BPD and Apnea, and did not reveal any statistical differences between NHFOV and DuoPAP during the respiratory support in preterm babies with RDS.
比较鼻塞高频振荡通气(NHFOV)和双水平气道正压通气(DuoPAP)在治疗呼吸窘迫综合征(RDS)早产儿中的安全性和有效性。
这是一项随机对照试验。选择 2020 年 1 月至 2021 年 11 月在淮北市妇幼保健院新生儿重症监护病房接受治疗的 43 例患有 RDS 的早产儿作为研究对象。他们被随机分为 NHFOV 组(n = 22)和 DuoPAP 组(n = 21)。比较两组患儿在无创呼吸支持后 12 小时和 24 小时的一般情况,包括动脉血氧分压(PaO2)、二氧化碳分压(PaCO2)、氧合指数(OI)、72 小时内呼吸暂停发生率、无创呼吸支持时间、母亲高危因素、总吸氧时间、总胃肠喂养时间、颅内出血(IVH)、新生儿坏死性小肠结肠炎(NEC)、支气管肺发育不良(BPD)和呼吸暂停的发生率。
两组患儿在不同时间节点的 PaO2、PaCO2、OI、IVH 和 NEC 及 BPD 方面差异均无统计学意义(均 P >.05)。
在治疗 RDS 早产儿的呼吸支持中,NHFOV 和 DuoPAP 在 PaO2、PaCO2 和 OI 等终点和 IVH、NEC、BPD 和呼吸暂停等并发症方面没有差异。